Develop Business Strategies Of Systemic Sclerosis (Scleroderma) Market 2024

"The Latest Research Report OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Systemic Sclerosis (Scleroderma) Market

Systemic sclerosis (SSc) is a complex autoimmune disease that affects the skin and multiple internal organs. Common manifestations of SSc that are included in this report are skin fibrosis, lung fibrosis, and digital vasculopathy (including Raynauds phenomenon [RP], and digital ulcers [DUs]). Although the etiology is not completely understood, it is believed to be caused by environmental triggers within genetically susceptible individuals. The clinical presentation of the disease varies between patients and treatment is mostly directed at managing its complications within each internal organ, as there are no systemic or disease-modifying treatments that significantly alter the course of the disease. Most drugs used to treat SSc are off-label and include immunosuppressive agents for skin and lung fibrosis and vasodilatory agents to treat digital vasculopathy. GlobalData expects the launch of three drugs during the 2014 to 2024 forecast period, including two biologic agents for fibrosis (Genentech/Roches Actemra and BMS Orencia) and Allergans Botox to treat digital vasculopathy.

Highlights

Key Questions Answered

- With three drug launches, two of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect immunosuppressants?
- What do SSc specialists across the 7MM think about the evolving treatment landscape? How will the results from the Scleroderma Lung Study II and update to the 2009 EULAR guidelines affect the management of SSc?
- What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
- According to KOLs, what are the most important unmet needs in SSc? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
- How do payers view the unmet needs for SSc and how do reimbursement practices affect drug availability?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/667471

Key Findings

- Biologics are expected to account for nearly half of the SSc market in 2024, with Roche/Genentechs Actemra emerging as a market leader.
- Reimbursement often poses a barrier to patients receiving proper therapy as evidence for use of off-label therapies in SSc is often lacking.
- Unmet needs are expected to remain after the forecast period, as there are no antifibrotic or disease-modifying therapies expected to launch for SSc.
- Several companies have been granted orphan designation and others from the European Medicines Agency (EMA), FDA, and Ministry of Health, Labour and Welfare (MHLW), which all provide incentives for drug development in this area.

Scope

- Overview of SSc, including etiology, pathophysiology, symptoms, and treatment recommendations.
- Annualized SSc market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SSc market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Roche/Genentechs Actemra, Roche/Genentechs Rituxan, BMSs Orencia, and Allergans Botox.
- Analysis of the current and future market competition in the global SSc market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/667471/opportunityanalyzer-systemic-sclerosis-scleroderma-opportunity-analysis-and-forecast-to-2024-market-research-reports

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and identify companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the SSc market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SSc market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global SSc market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/667471

Table of Contents

1 Table of Contents 8
1.1 List of Tables 13
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 24
3.2 Symptoms 28
3.3 Disease Management 30
3.3.1 Diagnosis 30
3.3.2 Treatment 32
4 Epidemiology 47
4.1 Disease Background 47
4.2 Risk Factors and Comorbidities 47
4.3 Global Trends 50
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 67
4.4.3 Forecast Assumptions and Methods 67
4.5 Epidemiological Forecast for SSc (2014-2024) 80
4.5.1 Diagnosed Prevalent Cases of SSc 80
4.5.2 Age-Specific Diagnosed Prevalent Cases of SSc 81
4.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc 84
4.5.4 Age-Standardized Prevalence of SSc 85
4.5.5 Diagnosed Prevalent Cases of SSc with RP and SSc with DU 86
4.5.6 SSc Segmented into lSSc and dSSc 88
4.5.7 Sex-Specific Diagnosed Prevalent Cases of lSSc 89
4.5.8 Sex-Specific Diagnosed Prevalent Cases of dSSc 90
4.5.9 Diagnosed Prevalent Cases of dSSc with ILD and Cases with Kidney Disease 91
4.6 Discussion 92
4.6.1 Epidemiological Forecast Insight 92
4.6.2 Limitations of the Analysis 93
4.6.3 Strengths of the Analysis 94
5 Current Treatment Options 95
5.1 Overview 95
5.2 Product Profiles - Tissue Fibrosis 97
5.2.1 Mycophenolate Mofetil 98
5.2.2 Methotrexate 103
5.2.3 Cyclophosphamide 106
5.2.4 Glucocorticoids 110
5.2.5 Azathioprine 115
5.3 Product Profiles - Vasculopathy 117
5.3.1 Tracleer (bosentan) 119
5.3.2 Calcium Channel Blockers 124
5.3.3 Phosphodiesterase 5 Inhibitors 127
5.3.4 Prostacyclins 130
5.3.5 Angiotensin Receptor Blockers 135
5.3.6 Selective Serotonin Reuptake Inhibitors 137
5.4 Other Therapies 140
6 Unmet Needs Assessment and Oppportunity Analysis 143
6.1 Overview 143
6.2 Lack of Anti-Fibrotic Drugs 144
6.2.1 Unmet Need 144
6.2.2 Gap Analysis 145
6.2.3 Opportunity 147
6.3 Lack of Disease-Modifying Therapies 148
6.3.1 Unmet Need 148
6.3.2 Gap Analysis 149
6.3.3 Opportunity 150
6.4 Identification of Prognostic Biomarkers 151
6.4.1 Unmet Need 151
6.4.2 Gap Analysis 153
6.4.3 Opportunity 153
6.5 Earlier Referral and Treatment 153
6.5.1 Unmet Need 153
6.5.2 Gap Analysis 155
6.5.3 Opportunity 155
6.6 Lack of Safe and Effective Therapies 156
6.6.1 Unmet Need 156
6.6.2 Gap Analysis 158
6.6.3 Opportunity 158

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.